News Sentiment

EBS sentiment intelligence

Emergent Biosolutions Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 49 Balanced news tone 58 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 8.05 Week of 10 Jul 2026
Weighted tone 49/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

79/100 classification confidence.

Company focus 58

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-2.8% over one week, -3.2% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Negative

Lobbying Update: $510,000 of EMERGENT BIOSOLUTIONS INC lobbying was just disclosed

Market Reaction

Balanced read

59/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 79/100 classification
One-week reaction -2.8% Price reacting lower
Trend fit Trend inactive -3.2% over four weeks
Fair value 14.6% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 6
Neutral 41
Negative 11

Relevance

Why the article matched

Direct first
Direct company coverage 58
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
TradingView 6
simplywall.st 6
GlobeNewswire 5
Moomoo 4
TradingKey 4
Market source 4
Stocktwits 3

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 11
Deals and strategy 8
Regulatory and legal 2
Balance sheet 2
Analyst action 2
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-58 of 58
Stock Titan Direct company coverage

[Form 4] Emergent BioSolutions Inc. Insider Trading Activity

Emergent BioSolutions Inc.'s EVP and CFO, Richard S. Lindahl, reported a routine tax-related disposition of 3,964 common stock shares at $8.00 each. These shares were withheld to cover taxes associated with the vesting of restricted stock units, not sold on the open market. Linda

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 19:39
Source
Stock Titan
Quartr Direct company coverage

Emergent BioSolutions (EBS) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary

This article summarizes Emergent BioSolutions' presentation at the Goldman Sachs 47th Annual Global Healthcare Conference 2026. It highlights the company's strategic focus on biodefense and opioid overdose treatment, its multi-year turnaround marked by significant cost reductions

Tone
Positive 72/100
Event
Market update
Published
08 Jun 2026 19:11
Source
Quartr